|Birth control type||Sterilization|
|Failure rates (first year, after occlusion)|
|User reminders||Additional methods until 3 month check by hysterosalpingogram|
|Advantages and disadvantages|
Essure is a permanent, non-surgical transcervical sterilization procedure for women developed by Conceptus Inc., a subsidiary of Bayer AG. It was approved for use in the United States on November 4, 2002.
Since 2013, the product has been the subject of controversy with women complaining of severe side effects leading to surgical extraction, and campaigner Erin Brockovich hosting a website where women can share their stories after having the procedure.
The procedure takes about 10 minutes, for a trained physician to perform and can be performed in a physician's office. General anesthesia is not required. Despite this, some women have reported considerable pain during the procedure.
Small, flexible inserts are placed into the fallopian tubes by a catheter passed from the vagina through the cervix and uterus. The insert contains inner polyethylene terephthalate fibers to induce inflammation causing fibrotic reaction and is held in place by flexible stainless steel inner coil and a dynamic outer nickel titanium alloy coil. Once in place, the device is designed to elicit tissue growth in and around the insert over a period of three months to form an occlusion or blockage in the fallopian tubes; the tissue barrier formed is supposed to prevent sperm from reaching an egg.
Unlike other forms of tubal ligation, no general anaesthetic nor incision through the abdomen is required. Similar to some other methods of birth control, initially additional forms of birth control must be continued for 3 months to prevent pregnancy until the method's effectiveness can be confirmed.
For the Essure method, three months after insertion a Radiologist performs a Fluoroscopic procedure called a hysterosalpingogram, to confirm that the fallopian tubes are completely blocked and that the patient can rely on the Essure inserts for birth control. A contrast agent (dye) is injected through the cervix, and an x-ray technologist takes photos of the Essure coils to ensure no contrast leaks past the Essure.
Following successful insertion and occlusional response, the Essure procedure is 99.74% effective based on 5 years of follow-up. Unfortunately, this info has also been proven false by a study done through Yale which states that the failure rate is closer to 11%.
The reported insertional failure rates are "failure to place 2 inserts in the first procedure (5%), initial tubal patency (3.5%), expulsion (2.2%), perforation (1.8%), or other unsatisfactory device location (0.6%)". Upon follow-up, occlusion is observed to have occurred in 96.5% of patients at 3 months with the remainder occluded by 6 months.
Cautions and warnings
The inserts are made from polyester fibers, nickel-titanium and stainless steel and solder and are safe to use with MRI equipment. Unlike many temporary methods of birth control, the Essure inserts do not contain or release hormones. The inserts do not prevent the transmission of sexually transmitted diseases.
The procedure is reported to be permanent and not reversible by the manufacturing company. Notwithstanding the manufacturer's position, several Essure reversals have been performed.
- Perforation, expulsion, or other unsatisfactory location of the insert
- Pregnancy and increased risk of ectopic pregnancy
- Pain, cramping, vaginal bleeding, menstrual pattern changes, light periods at first then longer, heavier periods lasting up to 6–8 weeks due to changing birth control methods to a non-hormonal solution
- Vasovagal response (fainting)
- Allergic reaction to the materials
- Heightened allergic response to other allergens
- heavy metal toxicity
- itchy, raised rash
- brain fog
- autoimmune disease symptoms
- weight gain
- hair loss
In 2013, the product made news in North America, with women complaining of severe side effects leading to surgical extraction. According to one article, women who have gotten pregnant are naming these children e-babies.
The FDA released a statement on October 25 2013, stating that since the product was approved in 2002 that it had received 943 reports of adverse events related to Essure, mainly for pain (606 of the complaints). An additional 1,000 more complaints have been sent to the FDA in a voluntary reporting system, but physicians are not obliged to report complaints.
A Facebook group called Essure Problems has 13,005 (as of 12/11/14) members who call the method "E-hell" and mostly complain about pain, bleeding and bloating from the device. Some say they've had coils break and perforate their internal organs. Erin Brockovich became involved in the controversy due to the laws of Federal preemption which presently stop women suing Bayer, and now hosts a website where women can share their stories after having the procedure.
Bayer has since provided two Toll-free telephone numbers for patient complaints, advises that women reporting adverse effects are "consistent with clinical trials and consistent with what the FDA is seeing", and further insists that it wants to hear from any women experiencing problems with Essure.
The U.S. Army Medical Command (MEDCOM) Contracting Center North Atlantic, located at MCAA NA Bldg T20, 6900 Georgia Avenue NW, Washington, DC 20307-5000 has announced its plan to procure 'ESSURE' Permanent Birth Control devices, using Taxpayer money, to permanently sterilize Female Military Service-persons and their Spouses. It is announced under Solicitation Number: W91YTZ-15-T-0044 (https://www.fbo.gov/spg/USA/MEDCOM/DADA15/W91YTZ-15-T-0044/listing.html).
- Conceptus Inc. was acquired by Bayer AG of Germany on June 5, 2013.
- "Essure Permanent Birth Control". U.S. Food and Drug Administration. Retrieved June 24, 2014.
- "Essure™ System - P020014". US Food and Drug Administration. 2009-06-29. Retrieved 2011-05-21.
- Hurskainen, R.; Hovi, S.; Gissler, M.; Grahn, R.; Kukkonen-Harjula, K.; Nord-Saari, M.; Mäkelä, M. (2010). "Hysteroscopic tubal sterilization: a systematic review of the Essure system". Fertility and Sterility 94 (1): 16–19. doi:10.1016/j.fertnstert.2009.02.080. PMID 19409549.
- "Women report complicatidiseasesons from Essure birth control". Chicago Tribune. Retrieved March 2, 2014.
- Regan Morris (June 24, 2014). "Erin Brockovich calls for end to Bayer's Essure". BBC News, Los Angeles. Retrieved June 24, 2014.
- Miño M, Arjona JE, Cordón J, Pelegrin B, Povedano B, Chacon E. Success rate and patient satisfaction with the Essure sterilisation in an outpatient setting: a prospective study of 857 women. BJOG. 2007 Jun;114(6):763-6.
- "Essure Confirmation Test". Conceptus Inc. Retrieved 2011-05-30.
- control methodsbyConceptus/Understanding/ClinicalTesting/tabid/58/Default.aspx "Clinical Testing". Essure. Conceptus. Retrieved 2006-12-12.[dead link]
- Smith RD (January 2010). "Contemporary hysteroscopic methods for female sterilization". Int J Gynaecol Obstet 108 (1): 79–84. doi:10.1016/j.ijgo.2009.07.026. PMID 19716128.
- "Prescribing Information" (PDF). Essure. Conceptus. 2005-09-08. Archived from the original on 2006-11-11. Retrieved 2006-12-12.
- "Doctors Confirm First Successful Essure Tubal Ligation Reversal". 2008-10-08. Retrieved 2010-02-15., referring to Dr. William A.C. Greene Jr. and Dr. Wendell Turner at Lakeshore Surgical Center
- Hurskainen R, Hovi SL, Gissler M, et al. (April 2009). "Hysteroscopic tubal sterilization: a systematic review of the Essure system". Fertil. Steril. 94 (1): 16–19. doi:10.1016/j.fertnstert.2009.02.080. PMID 19409549.